Traffic trends for Family Dollar Stores, Inc.(NYSE:FDO) deteriorated materially causing many investors to wonder if the decline was driven by a secular trend that will continue, or if there is something structurally broken at the company.
Family Dollar's lower customer traffic could be a sign that the company is ceding share to Dollar General (NYSE:DG) and several regional supermarket chains, including Wal-Mart Stores, Inc. (NYSE:WMT).
Competition in key grocery items was fierce in November and December, and FDO's relevance and value proposition in some discretionary categories appeared weaker.
BMO Capital Markets analyst Wayne Hood said the number of promotions and ads from Walmart and grocers during the fourth quarter pushing national brands and low price points/value were one of the highest the market has seen in a long time.
Top Low Price Stocks To Own For 2015: Vanguard Short-Term Bond ETF (BSV)
Vanguard Short-Term Bond ETF (the Fund) seeks to track the performance of a market-weighted bond index with a short-term, dollar-weighted average maturity. The Fund employs a passive management or indexing strategy designed to track the performance of the Barclays Capital U.S. 1-5 Year Government/Credit Bond Index (the Index). The Index includes all medium and larger issues of the United States Government, investment-grade corporate, and investment-grade international dollar-denominated bonds that have maturities of between 1 and 5 years and are publicly issued. The Fund invests by sampling the Index, meaning that it holds a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics. All of the Fund�� investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the Index. The Fund�� investment advisor is The Vanguard Group, Inc. Advisors' Opinion:- [By GURUFOCUS]
In addition to individual stocks several funds pay a monthly dividend. Below is a sampling of these:
Monthly Bond Funds- iShares Barclays 1-3 Year Credit Bond (CSJ) | Yield: 1.29%
- Vanguard Short-Term Bond ETF (BSV) | Yield: 1.25%
- Vanguard Intermediate-Term Bond ETF (BIV) | Yield: 2.96%
- Vanguard Long-Term Bond ETF (BLV) | Yield: 4.42%
Top 10 Low Price Stocks To Own For 2014: Belmont Resources Inc (BEA)
Belmont Resources Inc. (BEA), incorporated in 1978, is primarily engaged in the acquisition, exploration and development of resource properties. The Company is a uranium exploration and development company with key projects located in the Central Mineral Belt of Labrador, the Uranium City region of Northern Saskatchewan and the Reindeer / Wollaston Lake area bordering the Athabasca Basin of Northern Saskatchewan. BEA is focused on the development of these projects through joint venture agreements with other uranium companies. The Company�� properties include Saskatchewan property, Crackingstone and Orbit Lake, Labrador property, Tolmie property, Larder Lake property and Red Lake properties.
The Crackingstone and Orbit Lake claim comprises approximately 750 hectares in the Northern Mining District, Crackingstone River area, adjacent to JNR Resources Inc. (JNN) Crackingstone Project. BEA together with International Montoro Resources Inc. has signed an agreement in April and August 2006, to acquire 100% interest in three claim blocks (126 units approx. 4000 hectares (ha) in the Central Mineral Belt Uranium District, Labrador. Belmont's 64 unit (1024 ha) James Bay Lowlands property is located in north central Tolmie Township, Porcupine Mining Division, Ontario. Belmont also owns 100% interest in four claims (272 hectares) in Beatty Township, Larder Lake Mining Division, Northeastern, Ontario approx. 80 kilometer ENE from the city of Timmins. BEA and Montoro Resources Inc. have acquired 100% interest in two claim blocks (46 units) in the Red Lake Mining Camp: Bateman & Shaver Townships.
Advisors' Opinion:- [By Staff at Investopedia.com]
Making the Comparison
Gross domestic product figures can be released on a monthly or quarterly basis. For the United States, the Bureau of Economic Analysis (BEA), a branch of the US Commerce Department, releases final quarterly domestic figures—along with additional advanced or preliminary figures toward the end of each month. This report can also be released in either real or nominal conditions, the former being adjusted for the effects of inflation. The BEA also releases its GDP price index that has been used in competition with both consumer price index (CPI) and the personal consumption expenditures deflator as a gauge of consumer inflation.
Top 10 Low Price Stocks To Own For 2014: Amicus Therapeutics Inc.(FOLD)
Amicus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Its drugs are known as pharmacological chaperones, which selectively bind to the target protein, enhance the stability of the protein, help it fold into the three-dimensional shape, and allow proper trafficking of the protein, thereby increasing protein activity, enhance cellular function, and reduce cell stress. The company primarily focuses on lysosomal storage disorders and diseases of neurodegeneration. Its products under development include Amigal, which is in phase III for the treatment of Fabry disease; AT2220, which completed phase I study for the treatment of Pompe disease; and Plicera, that has completed phase I study for the treatment of Gaucher disease. The company has license and collaboration agreement with Glaxo Group Limited to develop and commerc ialize Amigal. The company was founded in 2002 and is based in Cranbury, New Jersey.
Advisors' Opinion:- [By Rick Munarriz]
5. You've got to know when to FOLD 'em
Investing in biotech upstarts can be pretty risky, and Amicus Therapeutics (NASDAQ: FOLD ) investors learned that the hard way this week. - [By John Udovich]
Since the start of 2014, small cap pharmaceutical stocks�Achillion Pharmaceuticals, Inc (NASDAQ: ACHN), Pernix Therapeutics Holdings Inc (NASDAQ: PTX) and Amicus Therapeutics, Inc (NASDAQ: FOLD)�are up 286.3%, 262.3% and 248.1%, respectively, making them some of the best performing pharmaceutical stocks for the year. However, a one year share performance, especially for anything in the volatile biotech or pharmaceutical sector, could be just a one time fluke. With that in mind, here is what you need to know or be warned about all three small cap pharmaceutical stocks:
Top 10 Low Price Stocks To Own For 2014: Constellation Brands Inc (STZ.B)
Constellation Brands, Inc., incorporated on December 4, 1972, is a producer and marketer of beer, wine and spirits with operations in the United States, Canada, Mexico, New Zealand and Italy. The Company�� beer brands include Corona Extra, Corona Light, Modelo Especial, Negra Modelo and Pacifico. Its wine brands consist of Robert Mondavi, Clos du Bois, Kim Crawford, Rex Goliath, Mark West, Franciscan Estate, Ruffino and Jackson-Triggs. The Company�� spirits brands include SVEDKA Vodka and Black Velvet Canadian Whisky. The Company has more than 100 brands in its portfolio, sales in approximately 100 countries and has about 40 facilities.
Beer
The Company imports markets and sells Mexican Beer Brands in all 50 states of the United States, which includes Corona Extra, Corona Light, Modelo Especial, Pacifico, Negra Modelo and Victoria. During the fiscal year ended February 28, 2014 (fiscal 2014), the Company had 15 imported beer brands in the United States. During fiscal 2014, the Company introduced Modelo Especial Chelada, a blend of Modelo Especial with flavors of tomato, salt and lime.
Wine and Spirits
The Company sells a range of wine brands across all categories, such as table wine, sparkling wine and dessert wine in the United States, Canada and New Zealand. Its wine produced in the United States is primarily marketed domestically and in Canada and the United Kingdom. The wine produced in Canada is primarily marketed domestically. Wine produced in New Zealand is primarily marketed in the United States, Canada, Australia, the United Kingdom and domestically. Wine produced in Italy is primarily marketed in the United States, Canada and domestically. In addition, it also exports its wine products to other world markets. Its spirits business, Svedka Vodka is imported from Sweden.
The Company sells its wine brands in the United States, which comprise its United States Focus Brands (Focus Brands) includes Arbor Mist, Inniskillin, Rex Go! liath, Black Box, Kim Crawford, Robert Mondavi, Blackstone, Mark West, Ruffino, Clos du Bois, Mount Veeder, Simi, Estancia, Nobilo, Toasted Head, Franciscan Estate, Ravenswood and Wild Horse. Its spirits brands include Black Velvet Canadian Whisky and Svedka Vodka.
Corporate Operations and Other
The Corporate Operations and Other segment includes corporate-related items, including executive management, corporate development, corporate finance, human resources, internal audit, investor relations, legal, public relations and global information technology.
The Company competes with Anheuser-Busch InBev, MillerCoors, Heineken, E&J Gallo Winery, The Wine Group, Trinchero, Treasury Wine Estates, Deutsch Family Wine & Spirits, Ste. Michelle Wine Estates, Kendall-Jackson, Andrew Peller, Kruger, Pernod Ricard, Lion Nathan, Diageo, Beam, Pernod Ricard, Bacardi and Brown-Forman.
Advisors' Opinion:- [By sandyinvestment]
As the craft beer industry has a considerable measure of room to develop, Boston Beer confronts rivalry from Molson Coors Brewing (TAP) and Constellation Brands (STZ) (STZ.B). Each of the three organizations have had great runs on the Street, however Boston Beer and Constellation Brands have been the greatest outperformers. We should investigate each of them.
Top 10 Low Price Stocks To Own For 2014: U.S. Dollar Index(DX)
Dynex Capital, Inc. operates as a mortgage real estate investment trust (REIT). It invests in residential and commercial mortgage-backed securities issued or guaranteed by a federally chartered corporation, non-agency mortgage-backed securities, and securitized mortgage loans, as well as unsecuritized single-family and commercial mortgage loans. The company finances its investments through a combination of repurchase agreements, and non-recourse collateralized financing, such as securitization financing Dynex Capital, Inc. has qualified as a REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal income tax, provided it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1987 and is based in Glen Allen, Virginia.
Advisors' Opinion:- [By Jon C. Ogg]
Dynex Capital Inc. (NYSE: DX) is rated as Buy, with a price target of $9.00, versus a recent price of $8.02. The book value was $8.94 at the end of last quarter and was projected to be $8.91 by the end of August.
- [By Eric Volkman]
Dynex Capital (NYSE: DX ) is maintaining its dividend. The company on Thursday declared a Q2 common stock distribution of $0.29 per share to be paid on July 31 to shareholders of record as of June 28.
Top 10 Low Price Stocks To Own For 2014: Actavis Inc (ACT)
Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.
Actavis Pharma Segment
Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company�� portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.
Actavis Specialty Brands Segment
The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company�� promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company�� Actavis Specialty Brands segment also receives other revenues consisting of co-promotion revenue and royaltie! s.
Anda Distribution Segment
The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians��offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.
The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,
Advisors' Opinion:- [By Ben Levisohn]
2. Actavis (ACT) settlement: Based on recent commentary by�Celgene and separate RBC notes on prior Actavis mgmt meetings, we expect rational market behavior. Case discovery ends in Feb ’15 and opens the door to settlement before Court begins mid-15.
- [By Stephen Quickel]
For example, we find several of these high-growth/moderate-PEG stocks in the healthcare sector, including Actavis (ACT), Gilead Sciences (GILD), Jazz Pharmaceutical (JAZZ), and Valeant Pharmaceuticals (VRX).
- [By Anna Prior]
Quebec-based drug company Duchesnay Inc. has sued Actavis (ACT) PLC, seeking to block a generic version of morning-sickness drug Diclegis.
Alcoa Inc.(AA) filed a shelf registration to offer up to $5 billion in mixed securities from time to time. The New York-based aluminum company didn’t disclose any other information, including the timing or underwriters of any possible future offerings in a filing on Friday with the Securities and Exchange Commission.
- [By MONEYMORNING.COM]
For its part, Actavis Plc. (NYSE: ACT) is a global pharmaceutical firm taking a dual approach to drugs - it makes both branded and lower-cost generics.
Top 10 Low Price Stocks To Own For 2014: iShares MSCI Germany ETF (EWG)
iShares MSCI Germany Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the German market, as measured by the MSCI Germany Index (the Index). The Index seeks to measure the performance of the German equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Tom Aspray]
A few weeks ago, I focused on some of the euro countries' debt levels, as well as the improvement in some of their manufacturing data. Their stock markets have continued to rally sharply as the iShares MSCI France (EWQ) is up over 13% since early July and is doing just slightly better than Germany (EWG).
No comments:
Post a Comment